Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00324948 · ClinicalTrials.gov registry record · Phase 2
Topical Alprostadil for Female Sexual Arousal Disorder
A Phase 2 study, sponsored by VIVUS.
- Completed
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
NCT00324948: Completed Phase 2 study, sponsored by VIVUS.
NCT00324948 is a Phase 2 study that has completed, run by VIVUS. The registered enrollment target is 300 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (126% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00324948, a Phase 2 study, has completed, sponsored by VIVUS.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
Study Summary
Approximately 300 patients with female sexual arousal disorder who meet eligibility criteria will be enrolled and randomized to receive either active drug or matching placebo. After a two-month, non-treatment period, patients will receive study drug for 6 months and will record information about sexual encounters in a daily diary. Study drug will be applied directly to the genital area 30-60 minutes before initiation of sexual activity. The endpoint of the study is based on the use of a standard measure of sexual function (FSEP).
Interventions
- DRUG Topical alprostadil (PGE-1)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2004-09 |
| Est. Completion | 2006-11 |
| Phase | Phase 2 |
What the finished NCT00324948 record still lists
NCT00324948 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (126% higher).
The record links to 0 conditions, and to 1 intervention - of which Topical alprostadil (PGE-1) is the first listed.
NCT00324948 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00324948 about?
NCT00324948 is a clinical study titled "Topical Alprostadil for Female Sexual Arousal Disorder". Approximately 300 patients with female sexual arousal disorder who meet eligibility criteria will be enrolled and randomized to receive either active drug or matching placebo. After a two-month, non-treatment period, patients will receive study drug for 6 months and will record information about sex...
What is the current status of trial NCT00324948?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2004-09. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00324948?
The interventions under investigation include: Topical alprostadil (PGE-1) (DRUG).
Who is sponsoring clinical trial NCT00324948?
This trial is sponsored by VIVUS, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00324948's enrollment target sits among peer trials
300 167th of 2000 higher than 1,813 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia